DIASTOLIC DYSFUNCTION AS AN EARLY INDICATOR OF ANTHRACYCLINE-INDUCED CARDIOTOXICITY IN BREAST CANCER PATIENTS: A SYSTEMATIC REVIEW
DOI:
https://doi.org/10.31435/ijitss.3(51).2026.5892Keywords:
Breast Cancer; Anthracycline Cardiotoxicity; Diastolic Dysfunction; Echocardiography; Cardio-Oncology; Early DetectionAbstract
Introduction: Breast cancer is one of the most common malignancies worldwide, and anthracyclines remain a cornerstone of its treatment. However, their use is associated with the risk of cardiotoxicity, which may lead to subclinical myocardial injury, progressive ventricular dysfunction, and heart failure. Although left ventricular ejection fraction is still widely used in routine surveillance, it often decreases relatively late. Therefore, increasing attention has been directed toward diastolic dysfunction as a possible earlier marker of anthracycline-induced cardiac injury.
Methods: A systematic review was conducted using the PubMed database. The search strategy included the terms “breast cancer” OR “breast neoplasms,” “anthracycline” OR “doxorubicin” OR “epirubicin,” and “diastolic dysfunction” OR “diastolic function.” The search was limited to studies published between 2010 and 2026, written in English, and conducted in humans. A total of 43 records were identified. After title and abstract screening, 15 full-text articles were assessed for eligibility. Fourteen studies met the inclusion criteria and were included in the final qualitative synthesis.
Results: The reviewed studies showed that anthracycline therapy was associated with worsening of conventional and tissue Doppler indices of diastolic function, including E/A ratio, deceleration time, e′ velocity, and E/e′ ratio, often despite preserved left ventricular ejection fraction. Several studies also demonstrated abnormalities in more advanced echocardiographic markers, such as diastolic strain rate, diastolic strain time, left atrial strain, and intrinsic wave velocity propagation. In longitudinal analyses, early diastolic dysfunction was associated with later worsening of global longitudinal strain, decline in left ventricular ejection fraction, or subsequent cancer therapy-related cardiac dysfunction.
Conclusions: Diastolic dysfunction appears to be a clinically relevant and potentially early marker of anthracycline-induced cardiotoxicity in breast cancer patients. Its earlier recognition may support closer cardio-oncology surveillance, improve risk stratification, and help identify patients who may benefit from earlier specialist evaluation and consideration of cardioprotective strategies before overt systolic dysfunction develops. Further prospective studies are needed to determine which diastolic parameters are the most sensitive and clinically useful in routine practice.
References
Appel, J. M., Sogaard, P., Mortensen, C. E., Skagen, K., & Nielsen, D. L. (2011). Tissue-Doppler assessment of cardiac left ventricular function during short-term adjuvant epirubicin therapy for breast cancer. Journal of the American Society of Echocardiography, 24(2), 200–206. https://doi.org/10.1016/j.echo.2010.12.004
Boyd, A., Stoodley, P., Richards, D., Hui, R., Harnett, P., Vo, K., Marwick, T., & Thomas, L. (2017). Anthracyclines induce early changes in left ventricular systolic and diastolic function: A single centre study. PLOS ONE, 12(4), e0175544. https://doi.org/10.1371/journal.pone.0175544
Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., & Jemal, A. (2024). Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 74(3), 229–263. https://doi.org/10.3322/caac.21834
Emerson, P., Stefani, L., Boyd, A., Richards, D., Hui, R., Altman, M., & Thomas, L. (2024). Alterations in left atrial strain in breast cancer patients immediately post anthracycline exposure. Heart, Lung and Circulation, 33(5), 684–692. https://doi.org/10.1016/j.hlc.2023.06.864
Hochstadt, A., Arnold, J., Rosen, R., Sherez, C., Sherez, J., Mor, L., Derakhshesh, M., Moshkovits, Y., Merdler, I., Arbel, Y., Kapusta, L., Rozenbaum, Z., Topilsky, Y., & Laufer-Perl, M. (2020). Diastolic strain time as predictor for systolic dysfunction among patients with active breast cancer. Echocardiography, 37(11), 1890–1896. https://doi.org/10.1111/echo.14791
Huang, F., Rankin, K., Sooriyakanthan, M., Signorile, M., Fan, C.-P. S., Thampinathan, B., Marwick, T. H., Osataphan, N., Yu, C., Koch, C. A., Amir, E., Hanneman, K., Abdel-Qadir, H., Wintersperger, B. J., & Thavendiranathan, P. (2025). Phenotypes of myocardial dysfunction on serial echocardiography and CMR in women with early-stage breast cancer. JACC: Cardiovascular Imaging, 18(5), 540–553. https://doi.org/10.1016/j.jcmg.2024.12.010
Huang, X., Fan, X.-Y., Cheng, Q., Zhang, J., Sun, J., Tang, Q.-Y., Deng, Y.-B., & Bi, X.-J. (2023). Intrinsic wave velocity propagation: A novel parameter for assessing the effect of anthracycline chemotherapy agents on cardiac diastolic function in breast cancer patients. Current Medical Science, 43(6), 1229–1237. https://doi.org/10.1007/s11596-023-2807-5
Lyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M., Bergler-Klein, J., Boriani, G., Cardinale, D., Castiglione, M., Čelutkienė, J., Cottin, Y., Dent, S., Dilaveris, P. E., Farmakis, D., López-Sendón, J. L., Ky, B., Lambrinou, E., Lenneman, C., Maack, C., . . . ESC Scientific Document Group. (2022). 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO), and the International Cardio-Oncology Society (IC-OS). European Heart Journal, 43(41), 4229–4361. https://doi.org/10.1093/eurheartj/ehac244
Mizia-Stec, K., Gościńska, A., Mizia, M., Haberka, M., Chmiel, A., Poborski, W., & Gąsior, Z. (2013). Anthracycline chemotherapy impairs the structure and diastolic function of the left ventricle and induces negative arterial remodelling. Kardiologia Polska, 71(7), 681–690. https://doi.org/10.5603/KP.2013.0154
Nagueh, S. F., Appleton, C. P., Gillebert, T. C., Marino, P. N., Oh, J. K., Smiseth, O. A., Waggoner, A. D., Flachskampf, F. A., Pellikka, P. A., & Evangelista, A. (2009). Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Journal of the American Society of Echocardiography, 22(2), 107–133. https://doi.org/10.1016/j.echo.2008.11.023
Plana, J. C., Galderisi, M., Barac, A., Ewer, M. S., Ky, B., Scherrer-Crosbie, M., Ganame, J., Sebag, I. A., Agler, D. A., Badano, L. P., Banchs, J., Cardinale, D., Carver, J., Cerqueira, M., DeCara, J. M., Edvardsen, T., Flamm, S. D., Force, T., Griffin, B. P., . . . Lancellotti, P. (2014). Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: A report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Journal of the American Society of Echocardiography, 27(9), 911–939. https://doi.org/10.1016/j.echo.2014.07.012
Serrano, J. M., González, I., Del Castillo, S., Muñiz, J., Morales, L. J., Moreno, F., Jiménez, R., Cristóbal, C., Graupner, C., Talavera, P., Curcio, A., Martínez, P., Guerra, J. A., & Alonso, J. J. (2015). Diastolic dysfunction following anthracycline-based chemotherapy in breast cancer patients: Incidence and predictors. The Oncologist, 20(8), 864–872. https://doi.org/10.1634/theoncologist.2014-0500
Serrano, J. M., Mata, R., González, I., Del Castillo, S., Muñiz, J., Morales, L. J., Espinosa, M. J., Moreno, F., Jiménez, R., Cristobal, C., Graupner, C., Talavera, P., Gutierrez Landaluce, C., Curcio, A., Alonso, J., Guerra, J. A., & Alonso, J. J. (2023). Early and late onset cardiotoxicity following anthracycline-based chemotherapy in breast cancer patients: Incidence and predictors. International Journal of Cardiology, 382, 52–59. https://doi.org/10.1016/j.ijcard.2023.04.026
Stoodley, P. W., Richards, D. A. B., Boyd, A., Hui, R., Harnett, P. R., Meikle, S. R., Clarke, J. L., & Thomas, L. (2013). Altered left ventricular longitudinal diastolic function correlates with reduced systolic function immediately after anthracycline chemotherapy. European Heart Journal–Cardiovascular Imaging, 14(3), 228–234. https://doi.org/10.1093/ehjci/jes139
Timóteo, A. T., Moura Branco, L., Filipe, F., Galrinho, A., Rio, P., Portugal, G., Oliveira, S., & Ferreira, R. C. (2019). Cardiotoxicity in breast cancer treatment: What about left ventricular diastolic function and left atrial function? Echocardiography, 36(10), 1806–1813. https://doi.org/10.1111/echo.14487
Upshaw, J. N., Finkelman, B., Hubbard, R. A., Smith, A. M., Narayan, H. K., Arndt, L., Domchek, S., DeMichele, A., Fox, K., Shah, P., Clark, A., Bradbury, A., Matro, J., Adusumalli, S., Carver, J. R., & Ky, B. (2020). Comprehensive assessment of changes in left ventricular diastolic function with contemporary breast cancer therapy. JACC: Cardiovascular Imaging, 13(1 Pt 2), 198–210. https://doi.org/10.1016/j.jcmg.2019.07.018
World Health Organization. (2025, August 14). Breast cancer. https://www.who.int/news-room/fact-sheets/detail/breast-cancer
Yaylali, Y. T., Saricopur, A., Yurtdas, M., Senol, H., & Gokoz-Dogu, G. (2016). Atrial function in patients with breast cancer after treatment with anthracyclines. Arquivos Brasileiros de Cardiologia, 107(5), 411–419. https://doi.org/10.5935/abc.20160146
Zhang, K. W., Finkelman, B. S., Gulati, G., Narayan, H. K., Upshaw, J., Narayan, V., Plappert, T., Englefield, V., Smith, A. M., Zhang, C., Hundley, W. G., & Ky, B. (2018). Abnormalities in 3-dimensional left ventricular mechanics with anthracycline chemotherapy are associated with systolic and diastolic dysfunction. JACC: Cardiovascular Imaging, 11(8), 1059–1068. https://doi.org/10.1016/j.jcmg.2018.01.015
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Tomasz Mainka, Emil Sergejuk, Wojciech Kotlarski, Klaudia Magdalena Kotlarska
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
How to Cite
